The company name TAmiRNA is an abbreviation of “Triple-A microRNA”, which stands for:
"microRNAs with age-associated activities"
This means that TAmiRNA seeks to identify and characterize small non-coding RNA molecules referred to as “microRNAs”, which contribute to the process of aging or the development of age-related diseases. Ultimately, TAmiRNA uses this knowhow to develop novel medical applications of microRNAs as diagnostic tests or therapeutic drugs to enable personalized treatment of disease. TAmiRNA targets to improve patient stability and quality of life with increasing age, by providing solutions for early risk assessment of disease and combined therapeutic treatment solutions.
Find out more about the science behind TAmiRNA, its current research and development programs and offers for partnerships and collaborations: